Amarin Corporation plc EBITDA 2011-2025 | AMRN

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Amarin Corporation plc

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-67.4 M	-105 M	11.1 M	-19.1 M	-23.4 M	-108 M	-44.8 M	-64.8 M	-96.1 M	-57.1 M	-181 M	-116 M	-44.1 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
11.1 M	-181 M	-70.5 M

Quarterly EBITDA Amarin Corporation plc

2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-16 M	-	-	-	-12.9 M	-	-	-	-16.6 M	-	-3.24 M	-62.8 M	-27.7 M	-	-11.4 M	8.77 M	-970 K	-	-5.86 M	4.88 M	-23.7 M	-	-4.03 M	-2.19 M	-22.7 M	-	-21.8 M	-32.3 M	-21.9 M	-	-8.4 M	-11.4 M	-18.5 M	-	-15.2 M	-14.3 M	-23.1 M	-	-25.7 M	-26.7 M	-27 M	-	-24.8 M	-25.1 M	-25.5 M	-	-40.2 M	-48.7 M	-60 M	-	-34.2 M	-27.6 M	-18.8 M	-	-9.4 M	-15.2 M	-7.16 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
8.77 M	-62.8 M	-20 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
AC Immune SA ACIU	-79 M	$ 2.8	2.19 %	$ 229 M	Schweiz
ADiTx Therapeutics ADTX	-27.2 M	$ 2.49	-11.39 %	$ 32.8 K	USA
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
Abeona Therapeutics ABEO	-44.8 M	$ 4.59	-4.08 %	$ 98.1 M	USA
ARCA biopharma ABIO	-88.1 M	-	1052.0 %	$ 415 M	USA
Applied Genetic Technologies Corporation AGTC	-16.2 M	-	-	$ 26.5 M	USA
Akouos AKUS	-84.3 M	-	0.23 %	$ 488 M	USA
Amneal Pharmaceuticals AMRX	312 M	$ 12.12	-1.58 %	$ 3.74 B	USA
Axcella Health AXLA	-76.6 M	-	-16.42 %	$ 249 M	USA
Acer Therapeutics ACER	-24.5 M	-	2.71 %	$ 14 M	USA
Armata Pharmaceuticals ARMP	-39.9 M	$ 5.37	-20.68 %	$ 194 M	USA
Atreca BCEL	5.46 M	-	-11.76 %	$ 5.79 M	USA
Brainstorm Cell Therapeutics BCLI	-11.5 M	-	-2.5 %	$ 5.88 M	USA
argenx SE ARGX	-349 M	$ 919.62	2.76 %	$ 25 B	Niderland
Ascendis Pharma A/S ASND	-452 M	$ 203.0	-3.72 %	$ 5 B	Danmark
Achieve Life Sciences ACHV	228 K	$ 4.64	-0.32 %	$ 92 M	USA
BioDelivery Sciences International BDSI	37.3 M	-	-4.8 %	$ 255 M	USA
BeiGene, Ltd. BGNE	-396 M	-	0.49 %	$ 251 B	Cayman-islands
Acorda Therapeutics ACOR	-233 M	-	-24.86 %	$ 820 K	USA
Alterity Therapeutics Limited ATHE	-17.3 M	$ 3.36	2.73 %	$ 8.08 B	Australia
Acasti Pharma ACST	-16.7 M	-	4.01 %	$ 150 M	Canada
Bellerophon Therapeutics BLPH	-22.4 M	-	-74.18 %	$ 955 K	USA
BioLineRx Ltd. BLRX	-24.8 M	$ 3.29	-1.5 %	$ 908 M	Israel
BioMarin Pharmaceutical BMRN	581 M	$ 54.27	-1.38 %	$ 10.3 B	USA
Adaptimmune Therapeutics plc ADAP	-130 M	-	-15.15 %	$ 60.3 M	Britain
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
Baudax Bio BXRX	-56.6 M	-	0.59 %	$ 63 K	USA
AbbVie ABBV	9.9 B	$ 224.99	-0.01 %	$ 398 B	USA
Cara Therapeutics CARA	-121 M	-	-3.03 %	$ 260 M	USA
CymaBay Therapeutics CBAY	-101 M	-	-	$ 3.45 B	USA
ChemoCentryx CCXI	-127 M	-	-	$ 3.74 B	USA
BioNTech SE BNTX	15.3 B	$ 96.22	-1.21 %	$ 27.2 B	Germany
Codiak BioSciences CDAK	-64.2 M	-	-55.98 %	$ 2.15 M	USA
Adaptive Biotechnologies Corporation ADPT	-143 M	$ 18.75	-0.48 %	$ 2.76 B	USA
Avid Bioservices CDMO	-7.57 M	-	-	$ 789 M	USA
BioXcel Therapeutics BTAI	-66.9 M	$ 1.92	-7.01 %	$ 4.87 M	USA
Biogen BIIB	673 M	$ 179.76	1.11 %	$ 26.2 B	USA
Cerevel Therapeutics Holdings CERE	-442 M	-	-	$ 7.29 B	USA
ContraFect Corporation CFRX	-64.5 M	-	-5.16 %	$ 5.39 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
Beam Therapeutics BEAM	-394 M	$ 23.52	-2.22 %	$ 1.94 B	USA
AbCellera Biologics ABCL	-302 M	$ 3.45	-0.72 %	$ 1.02 B	Canada
Cabaletta Bio CABA	-73.2 M	$ 2.37	-2.67 %	$ 2.77 M	USA
Clearside Biomedical CLSD	-24.8 M	-	-	$ 25.3 M	USA
Celsion Corporation CLSN	-18.9 M	-	-6.63 %	$ 13.9 M	USA
Clovis Oncology CLVS	-217 M	-	-7.23 %	$ 13 M	USA
Advaxis ADXS	-35.9 M	-	-9.65 %	$ 45.9 M	USA
Checkmate Pharmaceuticals CMPI	-61.4 M	-	-	$ 231 M	USA
Chimerix CMRX	-93 M	-	-	$ 756 M	USA
Concert Pharmaceuticals CNCE	-76 M	-	-	$ 401 M	USA